RT Journal Article
SR Electronic
T1 Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.01.23286614
DO 10.1101/2023.03.01.23286614
A1 Turner, A.M.
A1 Li, L.
A1 Monk, I.R.
A1 Lee, J.Y.H.
A1 Ingle, D.J.
A1 Duchene, S.
A1 Sherry, N.L.
A1 Stinear, T.P.
A1 Kwong, J.C.
A1 Gorrie, C.L.
A1 Howden, B.P.
A1 Carter, G.P.
YR 2023
UL http://medrxiv.org/content/early/2023/03/05/2023.03.01.23286614.abstract
AB Bacterial pathogens such as vancomycin-resistant Enterococcus faecium (VREfm) that are resistant to almost all antibiotics are among the top global threats to human health. Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly and alarmingly been widely reported. The causes of such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show that the use of rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in liver disease patients, is causing resistance to this last-resort antibiotic in VREfm. We show that mutations within the bacterial RNA polymerase complex confer cross- resistance to both rifaximin and daptomycin. Furthermore, VREfm with these mutations are spread globally across at least 5 continents and 20 countries, making this a major yet previously unrecognised mechanism of resistance. Until now, rifaximin has been considered ‘low-risk’ for development of antibiotic resistance. Our study shows this is not the case and that widespread rifaximin use may be compromising the clinical efficacy of daptomycin, one of the major last-resort interventions for multidrug resistant pathogens. These findings demonstrate that unanticipated antibiotic cross-resistance may potentially undermine global strategies designed to preserve the clinical use of last-resort antibiotics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Health and Medical Research Council (NHMRC) of Australia (GNT1185213 and GNT1160745). BPH is supported by an NHMRC Investigator Grant (GNT1196103). JCK is supported by an NHMRC Early Career Fellowship (GNT1142613). AMT and NLS are supported by an Australian Government Research Training Program scholarship. The Controlling Superbugs study was supported by the Melbourne Genomics Health Alliance (funded by the State Government of Victoria, Department of Health and Human Services, and the 10 member organizations).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for analysis of patient data was received from the University of Melbourne Human Research Ethics Committee (study number 1954615.3)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data presented in the study are deposited under Bioprojects PRJNA565795, PRJNA433676, PRJNA856406, and PRJNA856406.